Twitter LinkedIn
    Friday, February 3
    Login
    0 Shopping Cart
    Twitter LinkedIn
    Private Equity InsiderPrivate Equity Insider
    • About Us
    • Digital Events
    • Our Network
      • Reach
      • Sponsors
      • Members
    Private Equity InsiderPrivate Equity Insider
    Home»Fundraising»Dr Martens makes £3.7bn market debut
    Fundraising

    Dr Martens makes £3.7bn market debut

    January 29, 20214 Mins Read
    LinkedIn Facebook Twitter Email WhatsApp
    LONDON - JANUARY 22nd: The exterior of Dr martens on January the 22nd 2015 in London England UK. Dr Martens is a leading boot and shoe specialist.
    Share
    LinkedIn Facebook Twitter Email WhatsApp

    Dr Martens stomped on to the stock market this morning with a £3.7 billion debut that values the business at more than ten times the amount its private equity owners paid six years ago, boosting hopes for the rush of listings that are waiting to follow.

    The boot maker, which has been revered by punks and popstars as an anti-establishment fashion symbol, priced its shares at 370p each, at the top of its initial range after its initial public offering was eight times oversubscribed.

    Permira, its private equity owner, sold 350 million shares in the stock market listing to raise £1.29 billion alongside other selling shareholders, which include 22 senior staff who will share awards more than £350 million. Kenny Wilson, 54, chief executive, is making about £58 million in the listing despite only joining in 2018 from Cath Kidston, which collapsed last year.

    Mr Wilson said: “We have been delighted by the strong levels of interest, engagement and support from such a high-quality selection of institutional investors. The successful transformation of Dr Martens is a great story and what is even more exciting is the huge potential ahead.”

    Shares in Dr Martens climbed when the market opened this morning before settling 51p, or 13.8 per cent, higher at 421p in mid-morning trading. Sources said that its boosted £4.2 billion market capitalisation values the business at roughly 18 times forward earnings. About 35 per cent of the business, or 1 billion shares, are now in public hands although shareholders are gearing up to sell another 53 million owing to the strong demand. It is understood that bankers brought forward the float from its expected listing date of Monday after having enough investor appetite to cover all the shares on offer within an hour of opening the order book.

    Dr Martens refers to itself as a “global brand that has empowered rebellious self-expression” and has been worn by The Smiths, Sex Pistols, Nirvana and more recently Miley Cyrus and Beyoncé. The brand traces its roots to postwar Munich, where Dr Klaus Martens developed an air-cushioned rubber sole to support his broken foot after a skiing accident. Its classic eight-eyelet lace-up boot was developed in 1960 when the Griggs family of shoemakers, based in a village in Northamptonshire, bought the right and produced working men’s boots with yellow stitching.

    The Griggs family, who kept a 10 per cent stake after selling to Permira, will be sitting on a £129 million windfall.

    Since Permira bought Dr Martens for £300 million in 2014 from the Griggs family its sales have multiplied almost six-fold to £672 million. In the past two years it has increased the number of boots sold from 7 million to 11 million after investing in its supply chain to push growth overseas to 60 countries. Only one in ten shoes are still made in the UK and customers pay a premium of £189 for a pair of 1460s made in Northampton compared to a £149 pair manufactured overseas.

    Dr Martens made £672.2 million sales in the year to March 31, 2020 and earnings before interest, tax, depreciation and amortisation of £184.5 million. The business has said that it expects earnings to grow in the “high teens” after growing earning before income tax, depreciation and amortisation to £86.3 million in the six months to September 30. Last year Permira bought Golden Goose, a luxury trainer brand, for £1.3 billion, about 15 times earnings. Dr Martens valuation ranks it ahead of Levis’ multiple but behind Canada Goose, maker of downfilled coats.

    Investors are understood to be enthused about Dr Martens’ ambitions overseas and its resilience during the crisis and lockdowns, although the brand is a stark contrast to the queue of technology-focused flotations that are expected this quarter. Moonpig is targeting a £1.2 billion stock market listing based on its positioning as a technology greeting platform. The cybersecurity firm Darktrace, the takeaway app Deliveroo, the payments group Transferwise and Trustpilot, a ratings website, are all tipped for listings this year.

    Source: The Times

    Related

    Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.

    Fundraising Investments PE Insider Private Equity
    Share. LinkedIn Facebook Twitter Email WhatsApp

    Related Posts

    Euroclear moves into $9.8 trillion private asset market with Goji buy

    December 21, 2022

    CAI raises over $1B for inaugural fund and co-investment programme

    November 18, 2022

    KKR looking to sell Canadian gas producer Westbrick for $1.13B

    November 18, 2022

    Carlyle targeting $1.6B for second renewables fund

    November 18, 2022

    Comments are closed.

    Other Articles

    Monroe Capital sponsors third SPAC – MCAP Acquisition Corporation

    March 2, 2021

    London’s Camden Market owner sets out stall for £1.5bn sale

    June 6, 2022

    Intriva Capital acquires stake in MoneyPlus Group

    February 27, 2021

    Brookfield, two others bid for Fortum’s assets

    February 15, 2021

    Private Equity Insider LLC
    1212 Avenue of the Americas
    New York City 10036
    USA

    [email protected]

    Twitter LinkedIn
    © 2023 Private Equity Insider LLC. All rights reserved.
    • About
    • Terms of Use
    • Cookie Policy
    • Privacy Policy
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.

    View Cart Checkout Continue Shopping

    Sign In or Register

    Welcome Back!

    Login to your account below.


    Lost password?